Published in Rheumatology (Oxford) on December 06, 2011
Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. Nat Commun (2015) 1.70
Qualifying unmet needs and improving standards of care in psoriatic arthritis. Arthritis Care Res (Hoboken) (2014) 1.43
The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries. Adv Ther (2015) 1.07
Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study. Arthritis Care Res (Hoboken) (2014) 0.94
PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus. Ann Rheum Dis (2015) 0.90
Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set. RMD Open (2016) 0.88
Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. Rheumatol Ther (2016) 0.86
A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values. Patient Relat Outcome Meas (2015) 0.85
A novel, short, and simple screening questionnaire can suggest presence of psoriatic arthritis in psoriasis patients in a dermatology clinic. Clin Rheumatol (2014) 0.82
General measures and quality of life issues in psoriasis. Indian Dermatol Online J (2016) 0.80
Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis. BMC Musculoskelet Disord (2014) 0.79
Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis. Arthritis Rheumatol (2016) 0.78
Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis. BMC Musculoskelet Disord (2016) 0.78
Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis. Arthritis Care Res (Hoboken) (2015) 0.78
Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety. Rheumatol Int (2014) 0.77
Quality of life and severity of skin changes in the dynamics of psoriasis. Postepy Dermatol Alergol (2016) 0.77
Safety and efficacy of adalimumab treatment in Japanese patients with psoriasis: Results of SALSA study. J Dermatol (2016) 0.76
Identifying a novel locus for psoriatic arthritis. Rheumatology (Oxford) (2015) 0.75
An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy. Open Access Rheumatol (2016) 0.75
Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis. Arthritis Res Ther (2017) 0.75
A multicenter, non-interventional study to evaluate patient-reported experiences of living with psoriasis. J Dermatolog Treat (2015) 0.75
Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis. Ann Rheum Dis (2017) 0.75
A rare coding allele in IFIH1 is protective for psoriatic arthritis. Ann Rheum Dis (2017) 0.75
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet (2012) 4.13
Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. Arthritis Rheum (2013) 4.02
Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol (2005) 3.04
Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet (2013) 2.87
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum (2005) 2.80
Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet (2010) 2.76
Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet (2010) 2.66
Development and assessment of users' satisfaction with the systemic lupus erythematosus disease activity index 2000 responder index-50 website. J Rheumatol (2012) 2.48
Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol (2008) 2.11
Repair of radiographic joint damage following treatment with etanercept in psoriatic arthritis is demonstrable by 3 radiographic methods. J Rheumatol (2011) 2.07
The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum (2010) 2.06
Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum (2008) 2.06
Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet (2012) 1.88
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis (2014) 1.88
Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. J Rheumatol (2007) 1.73
Is there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus? J Rheumatol (2011) 1.72
Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus. Kidney Int (2011) 1.63
Anti-dsDNA antibody testing by Farr and ELISA techniques is not equivalent. J Rheumatol (2006) 1.62
Consensus on a core set of domains for psoriatic arthritis. J Rheumatol (2007) 1.60
Risk factors for development of coronary artery disease in women with systemic lupus erythematosus. J Rheumatol (2009) 1.58
Serum autoantibodies that bind citrullinated fibrinogen are frequently found in patients with rheumatoid arthritis. J Rheumatol (2006) 1.54
Axial psoriatic arthritis: update on a longterm prospective study. J Rheumatol (2009) 1.53
Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol (2011) 1.52
Diffuse idiopathic skeletal hyperostosis in psoriatic arthritis. J Rheumatol (2013) 1.51
Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol (2013) 1.50
Hospitalizations of patients treated with anti-tumor necrosis factor-α agents -- a retrospective cohort analysis. J Rheumatol (2012) 1.49
Effect of psoriatic arthritis according to the affected categories of the international classification of functioning, disability and health. J Rheumatol (2010) 1.46
Qualifying unmet needs and improving standards of care in psoriatic arthritis. Arthritis Care Res (Hoboken) (2014) 1.43
Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment. J Rheumatol (2014) 1.42
Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum (2012) 1.40
Association of interleukin-23 receptor variants with ankylosing spondylitis. Arthritis Rheum (2008) 1.38
Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum (2003) 1.38
Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res (Hoboken) (2011) 1.35
Predictors for radiological damage in psoriatic arthritis: results from a single centre. Ann Rheum Dis (2006) 1.28
Peripheral neuropathy in patients with systemic lupus erythematosus. Semin Arthritis Rheum (2011) 1.23
A conditional Markov model for clustered progressive multistate processes under incomplete observation. Biometrics (2004) 1.18
Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J Rheumatol (2005) 1.17
The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis (2012) 1.15
Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. J Rheumatol (2003) 1.14
Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum (2009) 1.13
Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J Rheumatol (2006) 1.13
Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis (2007) 1.12
International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol (2007) 1.11
The effect of pregnancy on lupus nephritis. Arthritis Rheum (2004) 1.10
TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J Invest Dermatol (2011) 1.10
Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum (2007) 1.09
Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am (2005) 1.09
Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology (Oxford) (2010) 1.08
Systemic lupus erythematosus disease activity index 2000 responder index-50 website. J Rheumatol (2013) 1.07
Antihomocitrullinated fibrinogen antibodies are specific to rheumatoid arthritis and frequently bind citrullinated proteins/peptides. J Rheumatol (2014) 1.07
Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res (Hoboken) (2010) 1.06
Association of interleukin 23 receptor variants with psoriatic arthritis. J Rheumatol (2009) 1.06
Human leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis. Ann Rheum Dis (2011) 1.06
Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol (2008) 1.05
A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: Does the effect change over time? Arthritis Rheum (2007) 1.05
Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Ann Rheum Dis (2012) 1.05
Description and prediction of physical functional disability in psoriatic arthritis: a longitudinal analysis using a Markov model approach. Arthritis Rheum (2005) 1.04
International spondyloarthritis interobserver reliability exercise--the INSPIRE study: I. Assessment of spinal measures. J Rheumatol (2007) 1.04
Genome-wide meta-analysis of psoriatic arthritis identifies susceptibility locus at REL. J Invest Dermatol (2011) 1.04
Quality of life over time in patients with systemic lupus erythematosus. Arthritis Rheum (2008) 1.03
Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis (2013) 1.03
International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. Arthritis Rheum (2009) 1.02
Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis (2012) 1.02
Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Ann Rheum Dis (2011) 1.02
Prevalence of malignancy in psoriatic arthritis. Arthritis Rheum (2008) 1.01
Psoriatic arthritis screening tools. J Rheumatol (2008) 1.00
Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria. J Rheumatol (2009) 1.00
Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology (Oxford) (2011) 1.00
The 1000 Canadian faces of lupus: determinants of disease outcome in a large multiethnic cohort. J Rheumatol (2009) 1.00
Improved survival in psoriatic arthritis with calendar time. Arthritis Rheum (2007) 1.00
Genetics of psoriasis and psoriatic arthritis: update and future direction. J Rheumatol (2008) 0.98
The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. J Rheumatol (2013) 0.97
Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J Rheumatol (2010) 0.97
Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol (2009) 0.97
Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis. Arthritis Care Res (Hoboken) (2011) 0.96
Prolonged remission in systemic lupus erythematosus. J Rheumatol (2005) 0.96
Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. Ann Rheum Dis (2012) 0.95
Effect of lead exposure on the immune response of some occupationally exposed individuals. Toxicology (2003) 0.95
Systemic lupus international collaborating clinics renal activity/response exercise: comparison of agreement in rating renal response. Arthritis Rheum (2008) 0.94
Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. Arthritis Rheum (2008) 0.94
Incidence of arthritis in a prospective cohort of psoriasis patients. Arthritis Care Res (Hoboken) (2011) 0.93
Fatigue in systemic lupus erythematosus: contributions of disordered sleep, sleepiness, and depression. J Rheumatol (2006) 0.93
Longitudinal study of the bidirectional association between pain and depressive symptoms in patients with psoriatic arthritis. Arthritis Care Res (Hoboken) (2012) 0.92